

Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC - Form 8-K

BRAINSTORM CELL THERAPEUTICS INC
Form 8-K
November 23, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 18, 2004

BrainStorm Cell Therapeutics Inc.
(Exact name of registrant as specified in its charter)

Washington (State or other jurisdiction of incorporation)	333-61610 (Commission File Number)	912061053 (IRS Employer Identification No.)
---	--	---

36 Derech Bait Lechem
Jerusalem, Israel 77002
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code 011-972-2-6737445

Golden Hand Resources, Inc.
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.03. Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year

On November 15, 2004, our board of directors authorized an amendment to our Articles of Incorporation to change the name of our Company from "Golden Hand Resources Inc." to "BrainStorm Cell Therapeutics Inc." We are changing the name

Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC - Form 8-K

of the Company to better reflect our business objectives going forward in the stem cell research arena. On November 18, 2004, we filed such amended Articles of Incorporation with the State of Washington and we have requested from the OTC Bulletin Board that our trading symbol be changed as well to reflect our new name. We expect to begin trading under our new symbol (BCLI.OB) beginning November 24, 2004. A copy of the Articles of Amendment to our Articles of Incorporation reflecting this change is attached hereto as Exhibit 3.i.01. A copy of a press release regarding this announcement is attached as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits

(c) Exhibits.

3.i.01 Articles of Amendment to Articles of Incorporation

99.1 Press Release dated November 23, 2004

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 22, 2004

BRAINSTORM CELL THERAPEUTICS INC.

/s/ Yaffa Beck

Name: Yaffa Beck

Title: President & CEO

EXHIBIT INDEX

Exhibit Number	Description
-----	-----
3.i.01	Articles of Amendment to Articles of Incorporation
99.1	Press Release dated November 23, 2004